Arthex announces regulatory milestones met in its program to develop ATX-01 in Myotonic Dystrophy Type 1

VALENCIA, Spain, Dec. 14, 2022 /PRNewswire/ -- Arthex Biotech S.A., a pre-clinical-stage biotechnology company pioneering innovative microRNA modulating approaches to diseases with high unmet medical needs, today announced that it has met key regulatory milestones in its program to...

Click to view original post